Avenue Therapeutics, Inc. (ATXI)
- Previous Close
0.1330 - Open
0.1350 - Bid --
- Ask 0.1367 x 100
- Day's Range
0.1250 - 0.1377 - 52 Week Range
0.1130 - 1.2500 - Volume
320,639 - Avg. Volume
1,568,065 - Market Cap (intraday)
5.754M - Beta (5Y Monthly) -0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9800 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.75
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
www.avenuetx.comRecent News: ATXI
Performance Overview: ATXI
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATXI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATXI
Valuation Measures
Market Cap
5.71M
Enterprise Value
3.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.39
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-209.03%
Return on Equity (ttm)
-535.10%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.38M
Diluted EPS (ttm)
-0.9800
Balance Sheet and Cash Flow
Total Cash (mrq)
1.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-13.49M
Research Analysis: ATXI
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell